Last updated: October 25, 2026
DynaCirc was an oral nicardipine hydrochloride brand used for hypertension. Its commercial value declined after generic nicardipine entered the U.S. market and physicians shifted toward lower-cost generic therapy and alternative calcium-channel blockers. DynaCirc does not appear to have a meaningful current branded revenue base, and public filings do not provide a reliable standalone sales series for the product.
The product’s economic history is best understood in three phases:
- Original branded launch and adoption in hypertension.
- Generic erosion after loss of practical market exclusivity.
- Commercial decline as generic nicardipine, amlodipine, felodipine, and other antihypertensive agents displaced branded DynaCirc.
DynaCirc should be distinguished from Cardene, the intravenous nicardipine product used in acute-care settings. The two products share the nicardipine active ingredient but address different markets, dosage forms, prescribing settings, and competitive dynamics.
What is DynaCirc and how does it compare with Cardene?
DynaCirc is an oral formulation of nicardipine hydrochloride, a dihydropyridine calcium-channel blocker. It was marketed in immediate-release capsules and controlled-release formulations under the DynaCirc and DynaCirc CR names.
Cardene is also based on nicardipine but is primarily associated with intravenous administration in hospital settings. DynaCirc competed in chronic outpatient hypertension, while Cardene IV competed in controlled acute blood-pressure management.
| Attribute |
DynaCirc |
Cardene |
| Active ingredient |
Nicardipine hydrochloride |
Nicardipine hydrochloride |
| Principal dosage form |
Oral capsule and controlled-release tablet/capsule formulations |
Intravenous injection |
| Main use |
Chronic hypertension |
Acute blood-pressure control |
| Primary channel |
Retail and outpatient prescribing |
Hospitals and critical-care settings |
| Main competitors |
Generic nicardipine, amlodipine, felodipine, nifedipine |
Generic IV nicardipine, clevidipine, labetalol, esmolol |
| Commercial profile |
Legacy oral brand with generic erosion |
Institutional acute-care product |
| Biosimilar exposure |
None |
None |
The distinction matters financially. DynaCirc’s market was exposed to routine generic substitution. Cardene’s hospital market has greater purchasing concentration, formulary control, and supply-contract influence.
When did DynaCirc lose exclusivity?
DynaCirc’s commercial exclusivity ended after generic nicardipine products became available in the United States. The product is a small-molecule drug, so its principal threat was conventional abbreviated new drug application competition rather than biosimilar competition.
The original oral formulation patents are historical and no longer provide meaningful commercial protection. The relevant economic barrier was removed many years ago through:
- Patent expiry or loss of enforceable exclusivity.
- FDA approval of generic oral nicardipine.
- Therapeutic substitution by other calcium-channel blockers.
- Broad availability of low-cost antihypertensive alternatives.
The product’s current value is therefore unrelated to patent-protected pricing. Any remaining commercial activity would depend on manufacturing economics, channel availability, supply reliability, or niche prescriber demand.
What patents protected DynaCirc and nicardipine formulations?
DynaCirc’s historic patent estate covered the nicardipine compound and pharmaceutical formulations. The key protection categories were:
Active pharmaceutical ingredient
Early nicardipine patents protected the chemical entity and related pharmaceutical salts. Those rights were directed to the active small molecule rather than to a biologic or complex delivery platform.
Oral dosage forms
The DynaCirc franchise included immediate-release oral capsules and controlled-release DynaCirc CR products. Formulation protection could include:
- Extended-release delivery.
- Dosage-form composition.
- Release-control excipients.
- Oral administration of nicardipine for hypertension.
- Dose ranges and administration schedules.
These rights are historical. They do not create a current barrier to generic nicardipine because the relevant patent terms have expired.
Method-of-use claims
DynaCirc labeling covered treatment of hypertension. Method-of-use patents for chronic blood-pressure reduction would have had limited durability as a commercial defense because the underlying indication was established, the active ingredient was known, and generic manufacturers could typically pursue labeling strategies that avoided protected uses where applicable.
Manufacturing and formulation barriers
Nicardipine is a conventional small molecule with established manufacturing chemistry. The product does not have the manufacturing complexity associated with monoclonal antibodies, antibody-drug conjugates, cell therapies, or long-acting injectable biologics.
Potential technical barriers include:
- Consistent impurity control.
- Particle-size and dissolution control.
- Controlled-release performance.
- Stability of the finished dosage form.
- Bioequivalence for modified-release products.
These barriers may affect the number of suppliers, but they do not restore the pricing power of the original DynaCirc brand.
What is the FDA regulatory status of DynaCirc?
DynaCirc was approved as an oral nicardipine product for hypertension. Its commercial status is different from its regulatory history.
A product can remain listed in FDA databases while no longer being actively marketed. FDA listings may distinguish between approved, discontinued, and withdrawn products. “Discontinued” generally describes marketing status and does not necessarily mean that FDA withdrew approval for safety or efficacy reasons.
DynaCirc’s regulatory position should be analyzed separately from generic nicardipine:
| Regulatory issue |
DynaCirc implication |
| Original approval |
Historical FDA approval for oral nicardipine |
| Current branded sales |
No meaningful publicly disclosed standalone revenue base |
| Generic competition |
Established and commercially significant |
| Safety withdrawal |
No basis to characterize the product as a safety withdrawal without a specific FDA determination |
| Orange Book relevance |
Historical listed-product and patent information may remain relevant for archival analysis |
| Biosimilar pathway |
Not applicable |
| ANDA pathway |
Applicable to generic oral nicardipine |
The commercial question is not whether nicardipine is a regulated drug. It is whether a branded DynaCirc product retains an economically defensible market. The answer is generally no in the U.S. retail hypertension market.
How many patents currently cover DynaCirc?
No currently enforceable patent estate appears to provide DynaCirc with meaningful market exclusivity in the United States. The historical estate may include multiple compound, formulation, and use patents, but those rights are not equivalent to active commercial protection.
For diligence purposes, patent count should be separated into three categories:
| Patent category |
Current commercial significance |
| Expired compound patents |
None for blocking generic entry |
| Expired oral formulation patents |
None for ordinary generic nicardipine |
| Active third-party or later formulation patents |
Potentially relevant only if tied to a separate product or delivery system |
A search limited to the DynaCirc trade name may undercount relevant rights because patent documents generally identify nicardipine hydrochloride, pharmaceutical compositions, or controlled-release formulations rather than the brand name.
What generic entry risks exist for DynaCirc?
Generic substitution is the dominant commercial risk and has already occurred. The principal generic entry mechanisms are:
- ANDA approval for immediate-release nicardipine capsules.
- Approval of generic controlled-release products where bioequivalence requirements are satisfied.
- Pharmacy-level substitution under state law and payer policy.
- Formulary preference for lower-cost calcium-channel blockers.
- Hospital and wholesaler purchasing based on contract price and supply continuity.
Generic erosion affects DynaCirc in several ways:
- Lower average selling price.
- Reduced pharmacy stocking.
- Lower prescriber brand recognition.
- Reduced promotional return on investment.
- Greater dependence on legacy demand.
- Loss of negotiating leverage with payers and wholesalers.
The remaining generic-market opportunity is primarily operational. A manufacturer may capture volume through competitive pricing, dependable supply, contract coverage, and regulatory compliance. It is unlikely to obtain premium pricing based on the DynaCirc name alone.
What formulation patents protected DynaCirc CR?
DynaCirc CR depended on controlled-release oral delivery. The technical rationale was to maintain nicardipine exposure over a longer interval than immediate-release dosing and to support chronic blood-pressure treatment.
Controlled-release products can face more complex generic development than standard capsules because applicants must demonstrate:
- Pharmaceutical equivalence.
- Bioequivalence.
- Comparable release characteristics.
- Consistent dissolution profiles.
- Acceptable food-effect performance, where relevant.
- Manufacturing consistency across commercial batches.
Those requirements can delay generic entry relative to a simple immediate-release capsule. They do not create permanent exclusivity. Once the applicable patents and regulatory exclusivities expire, the formulation becomes subject to generic competition.
The commercial strength of a controlled-release formulation is also limited when competing drugs offer once-daily dosing, broad guideline familiarity, or lower cost. Amlodipine, for example, became a major outpatient competitor because of its long duration, extensive clinical use, and generic availability.
Which companies challenged or displaced DynaCirc?
DynaCirc faced competition from two groups.
Generic manufacturers
Generic nicardipine suppliers competed directly on price and distribution. Public market conditions for generic drugs make supplier identity and market share variable because products can enter or exit based on profitability, manufacturing capacity, and shortage conditions.
Branded and generic calcium-channel blockers
The broader competitive set included:
- Amlodipine.
- Felodipine.
- Nifedipine.
- Isradipine.
- Verapamil and diltiazem in selected clinical settings.
- Other antihypertensive classes, including ACE inhibitors, angiotensin receptor blockers, and thiazide diuretics.
DynaCirc’s disadvantage was not limited to patent expiry. Nicardipine’s oral chronic-hypertension franchise also competed against drugs with stronger prescribing momentum, simpler dosing, broader guideline use, and larger generic supply bases.
How strong is the DynaCirc patent estate?
The current patent estate is commercially weak because the product’s principal protections are historical and generic competition is established.
| Patent-strength factor |
Assessment |
| Compound exclusivity |
Expired |
| Core oral formulation protection |
Expired or no longer commercially blocking |
| Method-of-use protection |
Limited current value |
| Manufacturing complexity |
Moderate but manageable |
| Generic substitutability |
High |
| Brand pricing power |
Minimal |
| Biosimilar barrier |
Not applicable |
| Litigation leverage |
Low |
| Reinvestment case |
Weak without a new delivery system or indication |
A stronger modern estate would require a new product architecture, such as a differentiated extended-release system, a novel combination product, or a clinically valuable indication supported by enforceable claims. The historic DynaCirc label does not provide that protection by itself.
What was DynaCirc’s financial trajectory?
DynaCirc’s financial trajectory followed the standard lifecycle of an older antihypertensive:
Launch and growth
The product benefited from the therapeutic expansion of calcium-channel blockers and the chronic nature of hypertension. Revenue during this period would have depended on branded pricing, physician adoption, retail distribution, and formulation differentiation.
Maturity
Sales growth would have slowed as the hypertension market became more crowded. DynaCirc faced pressure from other calcium-channel blockers and from antihypertensive therapies in different drug classes.
Generic erosion
After generic entry, brand revenue would have fallen sharply. Typical drivers include:
- Pharmacy substitution.
- Payer exclusion or higher brand copayments.
- Loss of promotional support.
- Wholesale destocking.
- Reduction in brand prescriptions.
- Declining average net price.
Post-exclusivity tail
Any remaining sales would likely reflect residual brand loyalty, limited distributor availability, or specific prescriber preferences. Such a tail is generally insufficient to support large-scale commercial investment.
No reliable standalone public revenue series for DynaCirc is available from major current pharmaceutical-company filings. Historical ownership and licensing arrangements also make direct comparison difficult because DynaCirc may have been reported within broader cardiovascular-product portfolios rather than as a separately disclosed business line.
What licensing deals affected DynaCirc?
DynaCirc’s commercial history involved legacy pharmaceutical ownership and commercialization arrangements. Public disclosures do not establish a current licensing structure that materially affects the U.S. market value of the brand.
For transaction analysis, the important point is that a license to the DynaCirc name or historical regulatory file would not by itself transfer meaningful exclusivity. A buyer would acquire value only if the transaction included one or more of the following:
- Active regulatory approvals.
- Reliable manufacturing capacity.
- Commercial distribution rights.
- A differentiated controlled-release product.
- Geographic rights in markets where generic competition remains limited.
- An established hospital or retail contract base.
Absent those assets, the brand is mainly a legacy name attached to an off-patent active ingredient.
What patent litigation and settlement risk affects DynaCirc?
DynaCirc has no apparent current litigation profile comparable to a protected blockbuster drug. The primary historic litigation risk would have involved generic entry, patent validity, infringement, or formulation claims.
For a generic nicardipine transaction, the relevant diligence questions are different:
- Whether an applicant received tentative or final approval.
- Whether any formulation patent remains listed.
- Whether the generic product is therapeutically equivalent.
- Whether the product has an active supply or manufacturing dispute.
- Whether state substitution rules permit automatic replacement.
- Whether shortage conditions create temporary pricing power.
Historical Paragraph IV activity may explain the timing of generic entry, but it does not create current brand protection after patent expiry and market displacement.
What is the geographic coverage of DynaCirc?
DynaCirc’s strongest historical commercial relevance was in the United States and other developed pharmaceutical markets with established hypertension treatment systems. Current geographic value varies by jurisdiction.
| Region |
Commercial assessment |
| United States |
Generic competition dominates; branded DynaCirc value is limited |
| European markets |
National reimbursement and generic substitution reduce brand opportunity |
| Japan |
Market value depends on local approval, manufacturer, and reimbursement status |
| Emerging markets |
Potential legacy demand, but price sensitivity is high |
| Hospital markets |
More relevant to IV nicardipine products than oral DynaCirc |
A geographic relaunch could be viable only where the brand retains recognition, generic penetration is incomplete, or local registration and distribution create an advantage. A global premium-brand strategy is not supported by the drug’s current exclusivity position.
What generic launch scenarios remain for DynaCirc?
Three scenarios are commercially plausible.
Scenario 1: Continued generic commoditization
This is the base case. Multiple suppliers compete on price, with intermittent changes in availability and limited differentiation.
Scenario 2: Supplier consolidation
If low prices cause manufacturers to exit, remaining suppliers may obtain temporary pricing improvement. That would reflect supply concentration, not DynaCirc patent strength.
Scenario 3: Reformulated or repositioned product
A new controlled-release, combination, or specialty-use product could create a separate commercial opportunity. It would require new clinical, regulatory, formulation, and patent investment. The legacy DynaCirc brand would not independently support premium pricing.
How does DynaCirc compare with competing antihypertensive drugs?
| Product category |
Generic penetration |
Dosing appeal |
Current commercial strength |
| DynaCirc oral nicardipine |
High |
Moderate |
Low |
| Amlodipine |
High |
Once daily |
High-volume generic |
| Nifedipine extended release |
High |
Once daily |
Established |
| Felodipine |
High |
Once daily |
Smaller niche |
| ACE inhibitors |
High |
Often once daily |
Broad |
| ARBs |
High |
Often once daily |
Broad |
| Cardene IV |
Generic and branded supply |
Acute-care use |
Specialty hospital market |
DynaCirc is disadvantaged by its mature generic status and by the availability of better-established once-daily antihypertensive options. Its clinical identity is stronger as part of nicardipine’s broader history than as a current branded franchise.
Key Takeaways
- DynaCirc is an oral nicardipine hydrochloride brand for hypertension.
- Its core patent and exclusivity protections are historical and no longer support premium pricing.
- Generic nicardipine is the primary commercial substitute.
- The product has no biosimilar risk because nicardipine is a small molecule.
- DynaCirc should not be confused with Cardene IV, which serves the hospital acute-care market.
- Public filings do not provide a reliable current standalone DynaCirc revenue series.
- Current brand value is limited unless linked to a surviving approval, differentiated formulation, supply advantage, or geographic niche.
- Any new commercial opportunity would require a new formulation, indication, combination, or distribution strategy.
- The patent estate is weak as a current barrier to generic entry.
- Revenue exposure is likely immaterial relative to large modern cardiovascular franchises.
Frequently Asked Questions
Is DynaCirc still marketed in the United States?
DynaCirc is not a meaningful current branded product in the U.S. hypertension market. Generic nicardipine and competing antihypertensives account for the practical treatment market.
Is DynaCirc the same drug as Cardene?
Both contain nicardipine hydrochloride, but DynaCirc is an oral product and Cardene is principally associated with intravenous use. Their markets and commercial economics differ.
Does DynaCirc have active Orange Book patents?
No historical DynaCirc patent estate appears to provide current effective market exclusivity for ordinary oral nicardipine. Orange Book status should be checked by product and formulation because listing status can differ from commercial availability.
Can a generic manufacturer launch nicardipine without a Paragraph IV challenge?
Yes. A generic applicant can file an ANDA using certifications appropriate to the listed patents. Once relevant patents and exclusivities expire, approval can proceed without a current patent dispute.
Is there biosimilar risk for nicardipine?
No. Nicardipine is a conventional small-molecule drug regulated through the generic-drug pathway, not the biosimilar pathway.
References
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
-
DailyMed. (n.d.). Nicardipine hydrochloride prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
National Library of Medicine. (n.d.). DynaCirc and nicardipine drug information. MedlinePlus and related drug-label resources. https://www.nlm.nih.gov/
